Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 8, 2026

Stock market today: Dow rises, S&P 500 and Nasdaq drop as defense stocks surge, tech slides

View original at finance.yahoo.com
Stock market today: Dow rises, S&P 500 and Nasdaq drop as defense stocks surge, tech slides US stocks moved mostly lower on Thursday, retreating further from all-time highs as investors took in fresh labor market data and grappled with President Trump's salvos on defense and Venezuela…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The jobs market got a positive sign to end a rather gloomy year, with planned layoff announcements hitting their lowest level of 2025 in December

    80% confidence

  • The world is set to face a critical copper shortage, driven by a boom in AI and defense spending, with global demand to grow by 50% by 2040

    80% confidence

  • US oil companies would be reimbursed if they invested in Venezuela

    80% confidence

  • The US could oversee Venezuela and control its oil revenue for years, potentially indefinitely going forward

    80% confidence

  • The US will lift export restrictions on Nvidia's H200 AI chips in December in exchange for a cut of its revenue

    80% confidence

  • Trump threatened to block share buybacks and dividend payments by US defense majors if they didn't invest in ramping up weapons operations

    80% confidence

  • Trump wants to boost military spending by 50% to $1.5 trillion a year, funded by proceeds from tariffs

    80% confidence

  • H200 sales to China would be materially additive to earnings for NVDA

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stock market today: Dow rises, S&P 500 and Nasdaq drop as defense stocks surge, tech slides — Source | Via News | ViaNews EU